CAS 1890222-25-9 Lesinurad (HCID 53465279)

개요

Lesinurad is a member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout. It has a role as a uricosuric drug. It is a monocarboxylic acid, a member of naphthalenes, an aryl sulfide, a member of triazoles, an organobromine compound and a member of cyclopropanes.

이름 및 식별자

우선 이름: Lesinurad
IUPAC: 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
현지명: 레시뉴라드
영어명: RDEA 594
분자식: C17H14BrN3O2S
분자량: 404.28

이름 및 동의어

LESINURAD878672-00-5RDEA594ZurampicRDEA 594RDEA-59409ERP08I3W2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acidCHEBI:90929DUZALLO COMPONENT LESINURADDTXSID2010260912-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

이름 더 보기

레시뉴라드LesinurdResinadRescindRecinardReginaldResinardLesinurasLesurinad

{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acidlesinuradum((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YL)SULFANYL)ACETIC ACIDRefChem:56326M04AB05DTXCID901510348

데이터베이스 식별자

CAS: 1890222-25-9、1890222-26-0、878672-00-5
PubChem CID: 53465279
DTXSID: DTXSID201026091
ChEMBL: CHEMBL2105720
ChEBI: CHEBI:90929
UNII: 09ERP08I3W、73WY698HZ7、Q59CAT99RS
EC Number: 689-245-8
Nikkaji: J3.671.265A

물성

구조 계산 물성

XLogP: 4.7
극성 표면적: 93.3 Å²
수소 결합 공여자 수: 1
수소 결합 수용자 수: 5
회전 가능 결합 수: 5
무거운 원자 수: 24
형식 전하: 0
복잡도: 479

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15

Human Drugs · 2건

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점: 171 oC · >171oC (dec.)
끓는 점: 643.7 · 643.7±65.0 °C(Predicted)
밀도: 1.72 · 1.72±0.1 g/cm3(Predicted)
저장 조건: -20 °C · -20°C Freezer, Under inert atmosphere
용해도: DMSO(약간 용해됨), 메탄올(약간 용해됨, 가열)
산도 계수 (pKa): 2.91 · 2.91±0.10(Predicted)
물리적 상태: 고체
색상: 흰색에서 황백색까지
InChI: InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
InChIKey: FGQFOYHRJSUHMR-UHFFFAOYSA-N
SMILES: C(O)(=O)CSC1N(C2=C3C(C=CC=C3)=C(C3CC3)C=C2)C(Br)=NN=1

안전 및 규제

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 2 notifications to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Hepatotoxicity · 1건

In large clinical trials, serum enzyme elevations were rare during lesinurad therapy and no more common than with placebo, and no instances of clinically apparent liver injury attributable to lesinurad were reported. Clinical experience with lesinurad therapy has been limited, but there have yet to be reports of clinically apparent liver injury attributable to its use.

안전 데이터

wgk: WGK 3
스토리지 클래스: 11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingLesinurad is extensively bound to proteins in plasma (greater than 98%), mainly to albumin.

PharmacodynamicsDose-dependent reductions in serum uric acid levels and increases in urinary uric acid excretion have been observed following single and multiple oral doses of lesinurad.

Mechanism of Action · 1건

Lesinurad inhibits the activity of uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4). URAT1 is a major transporter enzyme responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby increases excretion of uric acid.

Metabolism/MetabolitesLesinurad undergoes oxidative metabolism mainly via the polymorphic cytochrome P450 CYP2C9 enzyme.

FDA Pharmacological Classification · 6건

09ERP08I3W

LESINURAD

Established Pharmacologic Class [EPC] - Urate Transporter 1 Inhibitor

Mechanisms of Action [MoA] - Urate Transporter 1 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Lesinurad is an Urate Transporter 1 Inhibitor. The mechanism of action of lesinurad is as an Urate Transporter 1 Inhibitor and Cytochrome P450 3A Inducer.

응용 분야 · 2건

개요Approved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.

용도Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.

공급사100 곳

上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]

T&W GROUP021-61551611 13296011611 · [email protected]

Hunan Jibang Biological Technology Co., LTD13776644403 · [email protected]

上海波以尔化工有限公司[email protected]

艾琪康医药科技（上海）有限公司13661411401 · [email protected]

추가 설명

정의ChEBI: A member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout.